US FDA approves TMU clinical trials on preterm lung dysplasia

Source: College of Medicine

Published on 2018-05-22

Because bronchopulmonary dysplasia is a common chronic lung disease in preterm infants, School of Medicine Professor Chung-Ming Chen is conducting a trial to test human mesenchymal stem cells as a treatment for this condition.


Industry-university cooperation project team, from left: Vice President Chao-Ching Huang, Professor Chung-Ming Chen, Associate Professor Jia-ling Xie

The results help the project partners obtain approval for human clinical studies from the US Food and Drug Administration, and clinical trials began in March.

Taipei Medical University started an Industry-University Cooperation Research Program in August 2014. This research noted effects of human placental mesenchymal stem cells on brain injury and chronic lung disease; it also seeks to test stem cells’ usefulness against brain tumors in preterm infants. Vice President Chao-Ching Huang is working on these projects with Professor Chung-Ming Chen of the Medical School’s Pediatrics Department and Associate Professor Jia-ling Xie of the Translational Medicine doctoral program. A subproject led by Professor Chen improved neonatal rat lung development by exposing pups to high concentrations of oxygen to mimic human bronchial dysplasia and administering human mesenchymal stem cells intratracheally to reduce pulmonary hypertension.

While perinatal medicine has developed greatly, bronchopulmonary dysplasia is still a common complication of preterm birth and can lead to neonatal brain and organ insufficiency without drug treatment. Pulmonary hypertension is associated with bronchopulmonary dysplasia and fatalities in such cases.

Rats treated intratracheally with human mesenchymal stem cells on the fifth day after birth showed mesenchymal stem cell therapy increased vascular endothelial growth factor, reduced cytokines and connective tissue growth factor, improved alveolar development, and retarded angiogenesis and pulmonary fibrosis. This finding provides a new treatment for bronchial dysplasia in preterm infants.

Taipei Medical University establishing “OHDSI Taiwan Chapter,” joining global transnational research published in JAMIA

In collaboration with the Observational Health Data Sciences and Informatics (OHDSI), Taipei Medical University (TMU) established “OHDSI Taiwan Chapter” and participated in the "Uncovering exposures responsible for birth season– disease effects," a global research conducted by experts and scholars from Taiwan, the US, South Korea and other countries.

Taipei Medical University Celebrates 60 Years of Excellence

Taipei Medical University (TMU) celebrated the 60th anniversary of founding on October 30, 2020, with more than 450 dignitaries, professors, students and alumni joining the diamond jubilee.

2020 Taipei Medical University Oral Medical Service Teams Visited Rural Areas

In 2020, TMU College of Oral Medicine sent three medical service teams, comprised of faculty members and students, to visit remote areas in Taiwan.

Under pandemic, Taipei Medical University helped international students successfully join the TMU community

With the abundant support, fortunately, TMU helped 98% enrolled students successfully travel to Taiwan and join the TMU community under such a vicious pandemic, as of December 23, 2020.

TMU Outstanding International Alumni-Edi Sampurno Ridwan

Dr. Ridwan works on maintaining quality of and accessibility to education for students from all over Indonesia, which can be challenging especially considering the recent COVID-19 pandemic.

Taipei Medical University Hospital and Taiwan AI Labs screening for COVID-19 with AI Chest X-ray

The screening system applies AI to read chest X-rays uploaded by the hospital, and instantly provides clinicians with reliable values on the location of pneumonia and lung infection.

TMU and Academia Sinica officially launch the Taiwan Precision Medicine Initiative (TPMI)

The initiative is a large-scale clinical genetic research project conducted by the Academia Sinica in collaboration with 13 medical center-level hospitals in Taiwan.